TABLE 2

Sociodemographic characteristics, disease features and treatment regimens of the patient cohort

Subjects45
Foreign-born44 (97.8)
 Eastern Europe and Caucasus region36 (80.0)
 Africa5 (11.1)
 Asia3 (6.7)
HIV infection2 (4.4)
HCV infection21 (46.7)
Intravenous drug use with methadone substitution6 (13.3)
Pulmonary tuberculosis localisation44 (97.8)
Bilateral lung involvement#36 (81.8)
Cavities on chest radiography#39 (88.6)
Sputum smear positive at treatment start42 (93.3)
Sputum culture-positive at treatment start41 (91.1)
Any previous tuberculosis treatment34 (75.6)
Drugs contained in the treatment regimen
 Ethambutol20 (44.4)
 Pyrazinamide19 (42.2)
 Amikacin32 (71.1)
 Capreomycin3 (6.7)
 Moxifloxacin (400/800 mg daily)14 (31.1)/10 (22.2)
 Levofloxacin (1000 mg daily)8 (17.8)
 Ethionamide11 (24.4)
p-Aminosalicylic acid40 (88.9)
 Cycloserine32 (71.1)
 Linezolid43 (95.6)
 Clofazimine20 (44.4)
 Imipenem/clavulanic acid28 (62.2)
 Meropenem/clavulanic acid2 (4.4)
Age at admission years38 (30–42)
Serum albumin g·dL132.5 (27.5–36.9)
BMI kg·m219.6 (17.8–22.0)
Drugs included in the treatment regimen7 (6–8)
  • Data are presented as n, n (%) or median (interquartile range). HCV: hepatitis C virus; BMI: body mass index. #: n=44 subjects.